Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Urogenital Neoplasms 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

sipuleucel-T 1pamiparib 1gallium 68 PSMA-11 1fluzoparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × gallium 68 PSMA-11 × Clear all
NCT05670106 2026-02-13

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Novartis

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡